ANAB - Company ID 0001370053
ANAPTYSBIO, INC trades as ANAB and has a market capitalization of $1.93 B, making it the #2164 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $234.60M, up 157.0% from the prior year and net income of -$13.23M. This page tracks ANAPTYSBIO, INC through 678 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ANAPTYSBIO, INC's revenue grew from $16.68M to $234.60M, a compound annual growth rate of 34.1%. Net profit margin expanded from -25.5% to -5.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-21 |
| Major company event | 8-K | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business
Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise
To register for the conference, please visit https://hcwevents.com/royalty-company-conference .
Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders
The largest companies sharing ANAPTYSBIO, INC's SEC industry classification (pharmaceutical preparations).
ANAPTYSBIO, INC (ANAB) has a market capitalization of $1.93 B as of 2026-07-11, ranking #2164 among US-listed companies.
ANAPTYSBIO, INC reported revenue of $234.60M for fiscal year 2025, an increase of 157.0% year over year.
In its latest fiscal year ANAPTYSBIO, INC reported a net loss of $13.23M.